Medicare Enrolled
Dr. Matthew Butler, M.D.
Internal Medicine · San Antonio, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Butler from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Butler?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Butler
Dr. Matthew Butler is an internal medicine specialist in San Antonio, TX, with 15 years of NPI registration. Based on federal Medicare data, Dr. Butler performed 20,833 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Butler received a total of $39,335 from 16 pharmaceutical and/or device companies across 56 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Butler is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 15 years of NPI registration
▲ Top 2% volume in TX
$39,335 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗20,833
Medicare services
Top 2% in TX for internal medicine
Not available
Unique patients (not deduplicated)
$23
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 7,400 | $43 | $161 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
5,250 | $0 | $1 |
| BCG treatment for bladder cancer | 1,953 | $2 | $9 |
| Denosumab injection (Prolia/Xgeva) | 1,920 | $18 | $65 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
928 | $0 | $0 |
| Anti-nausea injection (ondansetron/Zofran) | 800 | $0 | $0 |
| Anti-nausea injection (Aloxi/palonosetron) | 360 | $1 | $5 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
260 | $92 | $313 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
228 | $76 | $538 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
174 | $12 | $46 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 174 | $3 | $10 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
156 | $58 | $222 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
155 | $99 | $386 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
121 | $2 | $7 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
116 | $22 | $86 |
| Magnesium sulfate injection, per 500 mg An injection of magnesium sulfate administered in 500 mg increments. |
96 | $1 | $2 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
64 | $22 | $85 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
62 | $49 | $188 |
| Bladder instillation of anti-cancer drug A procedure where an anti-cancer medication is introduced directly into the bladder. This method delivers the treatment locally to the bladder tissue. |
60 | $68 | $257 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
58 | $11 | $41 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
56 | $27 | $137 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
49 | $131 | $438 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
44 | $90 | $271 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
43 | $56 | $222 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
39 | $1 | $3 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
36 | $10 | $38 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
35 | $49 | $191 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
30 | $125 | $406 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
27 | $130 | $444 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
27 | $2 | $8 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
21 | $57 | $188 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
20 | $16 | $61 |
| New patient office visit, complex (60-74 min) | 17 | $172 | $536 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
16 | $26 | $97 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
14 | $1 | $3 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
13 | $43 | $163 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
11 | $25 | $99 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
2.0% high complexity
84.9% medium
13.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$39,335
Total received (2018-2024)
Avg $5,619/year across 7 years
Top 3% in TX for internal medicine
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
16
Companies
56
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,091
2023
$187
2022
$10,789
2021
$20,924
2020
$3,331
2019
$426
2018
$586
Payments by company (2024)
BeiGene USA, Inc.
$2,280
AstraZeneca Pharmaceuticals LP
$525
GENZYME CORPORATION
$143
Karyopharm Therapeutics Inc.
$125
Merck Sharp & Dohme LLC
$18
Top 3 companies account for 95.4% of 2024 payments
All-time payments by company (2018-2024) ›
GlaxoSmithKline, LLC.
$33,927
BeiGene USA, Inc.
$2,280
AstraZeneca Pharmaceuticals LP
$617
Celgene Corporation
$592
BeiGene, Ltd.
$525
Takeda Pharmaceuticals U.S.A., Inc.
$388
GENZYME CORPORATION
$346
Amgen Inc.
$249
Karyopharm Therapeutics Inc.
$125
E.R. Squibb & Sons, L.L.C.
$117
TESARO, Inc.
$59
Inari Medical, Inc.
$33
Novartis Pharmaceuticals Corporation
$22
Genentech USA, Inc.
$20
Merck Sharp & Dohme LLC
$18
Dova Pharmaceuticals
$16
Top 3 companies account for 93.6% of all-time payments
Associated products mentioned in payments ›
BLENREP · BRUKINSA · CALQUENCE · Doptelet · ELITEK · EMPLICITI · FLOWTRIEVER CATHETER · KEYTRUDA · Kyprolis · NINLARO · POLIVY · Revlimid · S · SARCLISA · SCEMBLIX · VELCADE · XGEVA · XPOVIO
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Internal medicine physicians in nearby ZIP areas
1,137
County median income
$70,571
Nearest hospital to ZIP centroid (approximate)
UNIVERSITY HEALTH SYSTEM
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Butler is a mixed practice specialist, with above-average Medicare volume (top 2% in TX), with 15 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Butler experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Butler performed 7,400 pembrolizumab injection (keytruda) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Butler receive payments from pharmaceutical companies?
Yes. Dr. Butler received a total of $39,335 from 16 companies across 56 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Butler's costs compare to other internal medicine physicians in San Antonio?
Dr. Butler's average Medicare payment per service is $23. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Butler) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Internal Medicine Physicians in San Antonio
Browse internal medicine physicians in San Antonio ranked by procedure volume and transparency data.
Highest volume
Top Internal Medicine Physicians in TX
Internal medicine physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Internal Medicine Physicians in TX
Which TX internal medicine physicians receive the most from drug and device companies.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
BeiGene USA, Inc. Payments to Doctors
See all physicians who received payments from BeiGene USA, Inc.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology